Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bivalirudin Clear all
Completed Phase 3 Interventional

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

NCT00093158
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2007 · Synced Oct 16, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional Results available

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

NCT01913483
View directory record Official record
Conditions
Peripheral Endovascular Interventions, Bleeding
Interventions
Bivalirudin, Unfractionated Heparin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Hot Springs, Arkansas • Stanford, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Carotid With Bivalirudin Angioplasty

NCT00812383
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 16, 2026, 11:13 PM EDT
Terminated Phase 4 Interventional Results available

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635
View directory record Official record
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 16, 2026, 11:13 PM EDT
Not listed Not applicable Interventional

A Prospective, Non-Randomized, Evaluation of Low-Risk Patients Undergoing Carotid Stenting With ANgiomax (Bivalirudin)

NCT01273350
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Carotid PTA and stenting
Device
Lead sponsor
SPSI d.b.a Capital Cardiovascular Associates
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Camp Hill, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

NCT00433966
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
Drug · Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
3,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antithrombotic Effects of Ticagrelor Versus Clopidogrel

NCT01642238
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 16, 2026, 11:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

NCT00073593
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Surgery
Interventions
Bivalirudin, Heparin, Protamine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 16, 2026, 11:13 PM EDT
Not listed Phase 4 Interventional

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin

NCT00370045
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bivalirudin with and without eptifibatide
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2006 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 16, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

NCT06080074
View directory record Official record
Conditions
Heart Failure, Cardiogenic Shock, Congenital Heart Disease, Cardiomyopathies
Interventions
Cardiohelp device (VA-ECMO), Heparin, Bivalirudin
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
0 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Palo Alto, California • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Study Of Angiomax In Infants Under Six Months With Thrombosis

NCT00043277
View directory record Official record
Conditions
Thrombosis
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
0 Years to 6 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2006 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

NCT00464087
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Bridgeport, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

NCT00079586
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Heparin, Bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 16, 2026, 11:13 PM EDT
Withdrawn Phase 4 Interventional

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

NCT00759083
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

NCT00093184
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Blue Island, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2006 · Synced Oct 16, 2026, 11:13 PM EDT
Withdrawn Phase 1 Interventional

Bivalirudin vs Heparin in ECMO Patients

NCT03707418
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication
Interventions
Heparin Sodium, Bivalirudin Injection [Angiomax]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 16, 2026, 11:13 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 16, 2026, 11:13 PM EDT
Active, not recruiting Not applicable Interventional

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

NCT03537586
View directory record Official record
Conditions
Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia
Interventions
Bivalirudin, Adenosine, Heparin, Pressure-Temperature Sensor Guidewire, Guiding Catheter
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 16, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 16, 2026, 11:13 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation

NCT03532399
View directory record Official record
Conditions
Drug Effect
Interventions
Bivalirudin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 16, 2026, 11:13 PM EDT